A Phase 2/3 study of CTX-471
Latest Information Update: 20 Aug 2024
At a glance
- Drugs CTX-471 (Primary)
- Indications Malignant melanoma; Solid tumours
- Focus Therapeutic Use
- Sponsors Compass Therapeutics
- 12 Aug 2024 According to a Compass Therapeutics media release, planning of this phase-2 monotherapy study is underway.
- 11 Mar 2021 New trial record
- 05 Mar 2021 According to a Compass Therapeutics media release, this study is expected to be initiated in the second half of 2022.